Jason Broderick

Articles

FDA Approves Atezolizumab for PD-L1 High NSCLC

May 19, 2020

The FDA has approved the single-agent atezolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer who have a high PD-L1 expression and no EGFR or ALK genomic tumor aberrations.